Back to today’s briefing

Story perspectives

FDA Submission for Vision-Restoring Therapy Could Transform Lives

7/15/2025

32 4

Summary

Story summary

Nanoscope Therapeutics is making waves by initiating a rolling submission for a Biologics License Application (BLA) to the FDA for MCO-010, a groundbreaking gene-agnostic therapy for retinitis pigmentosa. If granted approval by early 2026, this innovative treatment could illuminate the path to restored vision for countless legally blind patients across the U.S.

1 of 1

Story summary

Nanoscope Therapeutics is making waves by initiating a rolling submission for a Biologics License Application (BLA) to the FDA for MCO-010, a groundbreaking gene-agnostic therapy for retinitis pigmentosa. If granted approval by early 2026, this innovative treatment could illuminate the path to restored vision for countless legally blind patients across the U.S.